Novel Drug Delivery Systems Market Size, Analysis, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2025 – 2034

Novel Drug Delivery Systems Market Size

The global novel drug delivery systems market generated notable revenues in 2024 and is estimated to grow at a decent CAGR from 2025 to 2034, driven by the demand for more effective and targeted drug delivery processes that improve treatment outcomes, decrease side effects, and optimize patient compliance. The expansion of novel drug delivery systems is being driven by increased investment in technology and product development. This growth is supported by recent advances in nanotechnology, biotechnology, and materials science. These innovations have transformed conventional approaches to therapy.
 

Novel drug delivery systems are now increasingly used in the treatment of chronic diseases. In addition, market growth is being propelled by the global chronic disease burden and aging population that creates increasingly demanding chronic care needs. As per CDC.gov, nearly 60% of Americans suffer from at least one chronic disease, while 40% are affected by two or more chronic conditions.
 

Conventional drug delivery systems have limitations such as low bioavailability, unpredictable pharmacokinetics, and low patient compliance, NDDS technologies offer more exact, controlled, and sustained drug release. As NDDS technologies continue to increase as best practice and standard of care, relevant healthcare accelerated as these systems become integrated into everyday practice by pharmaceutical companies, care providers, and patients.
 

Novel Drug Delivery Systems Market Trends

One of the crucial trends is the shift toward personalized medicine, which is increasing the demand for customized and efficient drug delivery. As knowledge and understanding of genomics and diagnostics improve, drug delivery systems are being created that are personalized to reflect an individual’s genetic makeup, disease state, and treatment response. These improvements in drug delivery represent a movement away from one-size-fits-all drug and treat approaches, to individualized therapy, which is proven to improve clinical endpoints and reduce side-effects.
 

Another important trend is the increase in the use of nanotechnology in drug delivery. Nanocarriers, like nanoparticles, liposomes, and dendrimers, are now being used to encapsulate, stabilize, make soluble and more bioavailable drugs, and facilitate drug delivery. The nanocarrier delivery system allows drugs to be delivered to a specific location. This helps limit side effects while increasing drug concentration at the site of action.
 

Drug delivery systems are being developed and tested that combine the potential of nanotechnology and controlled drug release mechanisms to achieve a more precise delivery and dosing of a drug through its intended route of administration. Additionally, the drug delivery market is seeing growth in the development of non-invasive drug delivery systems like transdermal patches, inhalation aerosols, nebulizers, tablets, and oral suspension systems, as patients are looking for more efficient and less invasive options.
 

Novel Drug Delivery Systems Market Analysis

The novel drug delivery systems market from oral segment accounted for the largest share in 2024 and will grow at a notable CAGR through 2034. Oral delivery continues to be the preferred means of administering therapeutic agents, and the most convenient method of drug delivery for most patients. Oral delivery systems such as controlled-release tablets, oral nanoparticles, and enteric-coated formulations can provide drug delivery that has improved bioavailability and fewer side effects. There have been significant advancements in oral drug delivery in recent years.
 

Researchers have discovered new types of carriers to improve drug effectiveness. Some of these include solid lipid nanoparticles, cyclodextrins, and self-emulsifying drug delivery systems (SEDDS). These carriers are especially useful for drugs that do not dissolve well in water.They help enhance both the solubility and stability of such drugs.
 

Oral drug delivery systems are expected to continue to drive steady growth as pharmaceutical companies are escalating their R&D efforts to develop formulations to overcome the limitations of current oral dosage forms. Furthermore, the increasing pace of personalized medicine and the prevalence of chronic diseases such as diabetes and cardiovascular disorders are supporting the present demand for novel developmental approaches in NDDS systems.
 

The novel drug delivery systems market from controlled segment is projected to witness robust growth through 2034. This growth is driven by the increasing use of targeted delivery methods. Implantable devices also contribute significantly to segment expansion. These technologies offer high therapeutic efficacy while minimizing side effects, making them highly promising for future applications. The delivery systems are designed to release drugs at a pre-established rate over a sustained period. This is critical to achieving steadier plasma drug concentrations and ultimately better patient compliance and adherence.
 

Controlled drug release systems rely on and extensively employ technologies such as biodegradable polymers, micelles, hydrogels, and nanoparticles. Controlled drug release systems in all these formulations have been exceedingly beneficial in treating chronic disorders like cancer, whereby controlled drug release can lessen the adverse effects by limiting toxicity to healthy tissues while enhancing the overall treatment effect.  Also, controlled novel drug delivery systems can be tailored to release specific doses at intended intervals and eliminate individual patient risks of over- or under-dosing. The development of controlled drug delivery systems is largely driven by the growing interest in precision medicine and a heightened focus on the pharmacokinetics and pharmacodynamics of various therapeutic agents.
 

North America novel drug delivery systems market held the largest share in 2024 and is estimated to grow at a decent CAGR through 2034, because of its highly advanced healthcare sector increasing healthcare spending, and demand for new therapeutics. United States is a significant player in the NPDD market due to its abundance of pharmaceutical companies, innovative institutions of research, and higher prevalence of chronic diseases such as diabetes, cancer, and cardiovascular diseases. With some of the most favorable regulations and capital expenditures, this region has experienced earlier adoption and commercialization of NPDD systems than others.
 

Recent improvements in drug delivery systems included advancements in healthcare systems improving integration with biomedical technologies. In addition, North America is also leading the way in the convergence of drugs and technologies such as nanotechnology, 3D printing, and microencapsulation in drug delivery systems, all of which will change how drugs are delivered and used in practices. Personalized medicine and patient-oriented drug delivery are some trends from regions like North America.
 

Novel Drug Delivery Systems Market Share

Major players involved in the novel drug delivery systems industry include:

• Merck & Co. Inc.
• Pfizer
• F. Hoffman La Roche
• AstraZeneca
• Sanofi
• Johnson & Johnson
• GlaxoSmithKline
• Abbott Laboratories
• Bayer
• Novartis
   

Players in the novel drug delivery systems market are using a variety of tactics to improve their market footprint and competitive advantage. The primary tactic is offering a substantial amount of resources towards R&D to create new and differentiated drug delivery technologies. Many companies are noticing new technologies such as nanotechnology, 3D printing, and microencapsulation, which improved targeted drug delivery systems. Some companies are also forming strategic collaborations and partnerships with academic institutions, smaller biotechnology companies, and other pharmaceutical companies to create new drug delivery systems.
 

Moreover, companies are motivated to develop a more diverse product portfolio by entering new drug delivery modalities such as transdermal patches, injectable drug delivery devices, or oral formulations to meet a range of patient needs and preferences. Major market players are also focused on their presence in emerging markets where rising healthcare needs and improving healthcare infrastructure are expected to provide companies with substantial growth potential.
 

Novel Drug Delivery Systems Industry News

• In April 2025, DDL, a provider of package, product, and material testing services, opened a new Good Manufacturing Practice (GMP) lab focused on drug-delivery combination product testing. This expansion increased its ability to offer regulatory-compliant testing solutions, supporting the pharmaceutical, biotech, and combination product industries.
   
• In September 2024, in groundbreaking research, Gujarat Varsity scientists developed a novel drug delivery method that potentially revived the effectiveness of antibiotics against multi-drug-resistant microbes.